Compare KeyCorp (KEY) vs Novavax Inc (NVAX) Price & Performance

KeyCorp (KEY) trades at $20.10, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments in wealth and retail banking.

The outlook is supported by analyst consensus with a $25.00 price target and 60.79% buy ratings, though risks include volatile cash flows and competitive pressures. Revenue growth momentum and aggressive share buybacks provide upside potential, but investors should weigh the frozen dividend against peers and monitor interest rate impacts on net interest income.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.